R Mazzola1, F Ricchetti2, A Fiorentino2, N Giaj-Levra2, S Fersino2, U Tebano3, S Albanese4, S Gori5, F Alongi2. 1. Radiation Oncology Division, Sacro Cuore Don Calabria Cancer Care Center, Via Don A. Sempreboni 5, 37024, Negrar, Verona, Italy. rosariomazzola@hotmail.it. 2. Radiation Oncology Division, Sacro Cuore Don Calabria Cancer Care Center, Via Don A. Sempreboni 5, 37024, Negrar, Verona, Italy. 3. Radiation Oncology School, University of Padova, Padua, Italy. 4. Head and Neck Surgery, Sacro Cuore Don Calabria Cancer Care Center, Negrar, Verona, Italy. 5. Medical Oncology Sacro Cuore Don Calabria Cancer Care Center, Negrar, Verona, Italy.
Abstract
PURPOSE: The aim of the current analysis was to evaluate the effectiveness and tolerability of rapid onset opioid in a cohort of head and neck cancer (HNC) patients affected by painful mucositis influencing swallowing function during RT ± ChT with definitive or adjuvant intent. METHODS: A retrospective analysis was conduct on HNC patients during RT ± ChT that received fentanyl pectin na sal spray (FPNS) for incidental BTP due to painful mucositis 13 min before the main meals. The period of observation has been 90 days starting from the beginning of RT ± ChT. RESULTS: Forty HNC patients with incidental BTP due to painful mucositis treated with FPNS were analyzed. The mean NRS of untreated episodes of BTP was 5.73 ± 1.54 decreasing to 2.25 ± 2.45 with FPNS (median dose 100 mcg). During the pain treatment, the number of meals increased from 2.08 ± 0.35 to 2.868 ± 0.4 (p = 0.000), and the BMI remained stable (from 25.086 ± 3.292 to 25.034 ± 3.090; p = 0.448). The 94.9% of patients was satisfied or very satisfied for the rapidity of the effect, and 97.4% for the easiness and convenience in the use. CONCLUSIONS: FPNS showed an acceptable safety activity profile in predictable BTP due to painful mucositis in HNC patients during RT ± ChT. FPNS was also effective in reducing the mucositis sequelae and allowing the completion of RT scheduled scheme. Moreover, patients declared satisfaction in terms of ease of use.
PURPOSE: The aim of the current analysis was to evaluate the effectiveness and tolerability of rapid onset opioid in a cohort of head and neck cancer (HNC) patients affected by painful mucositis influencing swallowing function during RT ± ChT with definitive or adjuvant intent. METHODS: A retrospective analysis was conduct on HNC patients during RT ± ChT that received fentanyl pectin na sal spray (FPNS) for incidental BTP due to painful mucositis 13 min before the main meals. The period of observation has been 90 days starting from the beginning of RT ± ChT. RESULTS: Forty HNC patients with incidental BTP due to painful mucositis treated with FPNS were analyzed. The mean NRS of untreated episodes of BTP was 5.73 ± 1.54 decreasing to 2.25 ± 2.45 with FPNS (median dose 100 mcg). During the pain treatment, the number of meals increased from 2.08 ± 0.35 to 2.868 ± 0.4 (p = 0.000), and the BMI remained stable (from 25.086 ± 3.292 to 25.034 ± 3.090; p = 0.448). The 94.9% of patients was satisfied or very satisfied for the rapidity of the effect, and 97.4% for the easiness and convenience in the use. CONCLUSIONS: FPNS showed an acceptable safety activity profile in predictable BTP due to painful mucositis in HNC patients during RT ± ChT. FPNS was also effective in reducing the mucositis sequelae and allowing the completion of RT scheduled scheme. Moreover, patients declared satisfaction in terms of ease of use.
Entities:
Keywords:
Fentanyl nasal spray; Head and neck cancer; Mucositis; Pain; Radiotherapy
Authors: Marie Fallon; Carlo Reale; Andrew Davies; A Eberhard Lux; Kirushna Kumar; Andrzej Stachowiak; Rafael Galvez Journal: J Support Oncol Date: 2011 Nov-Dec
Authors: Shreerang A Bhide; Sarah Gulliford; Jack Fowler; Nicola Rosenfelder; Katie Newbold; Kevin J Harrington; Christopher M Nutting Journal: Radiother Oncol Date: 2010-09-07 Impact factor: 6.280
Authors: Dorothy M Keefe; Mark M Schubert; Linda S Elting; Stephen T Sonis; Joel B Epstein; Judith E Raber-Durlacher; Cesar A Migliorati; Deborah B McGuire; Ronald D Hutchins; Douglas E Peterson Journal: Cancer Date: 2007-03-01 Impact factor: 6.860
Authors: Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg Journal: Radiother Oncol Date: 2003-03 Impact factor: 6.280
Authors: R Mazzola; F Ricchetti; A Fiorentino; G Di Paola; S Fersino; N Giaj Levra; R Ruggieri; F Alongi Journal: Eur J Clin Nutr Date: 2016-04-13 Impact factor: 4.016